ArticleIranian journal of biotechnology2025
Article in Iranian journal of biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Interleukin-6 (IL-6) plays an important role in cancer metastasis. Therefore, it seems that inhibition of IL-6 may act as an anticancer agent. Objectives: This study examined the anti-proliferative and IL-6 signal transduction inhibitory effects of a mutant IL-6 receptor (mIL-6R) on an ovarian cancer cell line. Materials and Methods: The intein1-mIL-6R was expressed in Results: The highest solubility of mIL-6R was obtained at 20 °C, 0.5 mM IPTG. The highest level of intein1 cleavage occurred at 25 °C, 24 hours of incubation, and pH = 4 of cleavage buffer. Also, mIL-6R diminished the survival of OVCAR-3 cells compared to PBS (p-value = 0.024), with 48 hours IC50 of 1.117 μg/mL. Also, mIL-6R significantly reduced the expression of the JAK, STAT, and VEGF genes. Conclusion: The recombinant mIL-6R showed a strong concentration-dependent anti-proliferative effect on the OVCAR-3 cell line. However, it needs further evaluation for its potential activity against disorders associated with increased IL-6.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.